Neureka Health
Glossary
Glossary·Condition

Dementia / Alzheimer's disease

Also known as: dementia, Alzheimer's disease, AD, neurocognitive disorder, major neurocognitive disorder

Dementia is a syndrome of progressive cognitive decline severe enough to impair daily life; Alzheimer's disease is its most common cause, characterised by amyloid plaques, tau tangles, and gradual neurodegeneration.

A note on scope: This entry is informational — it describes what dementia and Alzheimer's disease are in the context of brain ageing research. It is not a diagnostic tool, and nothing here should be used to draw conclusions about any individual's health. Diagnosis requires clinical evaluation by a qualified professional.

Dementia

Dementia is a clinical syndrome — a collection of symptoms — rather than a single disease. It describes progressive decline in two or more cognitive domains (memory, language, attention, executive function, visuospatial skills) that is severe enough to interfere with daily life, and that represents a change from a previous level of functioning.

Dementia has many causes:

TypeApproximate share of cases
Alzheimer's disease~60–70%
Vascular dementia~15–20%
Lewy body dementia~5–10%
Frontotemporal dementia (FTD)~5–10%
Mixed pathologyCommon, particularly in older adults

Alzheimer's disease

Alzheimer's disease (AD) is the most common neurodegenerative cause of dementia. Its defining neuropathological features are:

  • Amyloid-β plaques — extracellular deposits of misfolded amyloid-β protein, particularly in regions of the default mode network
  • Neurofibrillary tangles — intracellular accumulations of hyperphosphorylated tau protein, initially in the hippocampus and entorhinal cortex, spreading outward with disease progression
  • Neurodegeneration — progressive loss of synapses and neurons, reflected on MRI as characteristic atrophy beginning in medial temporal structures

Importantly, these pathological changes begin 15–25 years before clinical symptoms. There is now a well-developed biological staging system (the amyloid/tau/neurodegeneration, or AT(N) framework) that defines Alzheimer's disease by its biology rather than its clinical presentation.

The continuum from ageing to dementia

Alzheimer's disease and normal brain ageing exist on a continuum. Both involve gradual cortical thinning, memory-related network changes, and increased CSF biomarker concentrations — but at different rates and magnitudes. This is one reason brain age models, which learn the typical rate of structural change in healthy ageing, produce larger brain age gaps in people who go on to develop dementia — sometimes years before diagnosis.

Intermediate stages include:

  • Subjective cognitive decline (SCD) — self-reported memory concerns without objective impairment
  • Mild cognitive impairment (MCI) — objective cognitive decline not yet affecting daily function; roughly 10–15% per year progress to dementia

Risk and protective factors

Established modifiable risk factors for dementia (Lancet Commission, updated 2024) include:

  • Hearing loss, depression, social isolation, physical inactivity
  • Hypertension, obesity, diabetes, smoking, excessive alcohol
  • Traumatic brain injury, air pollution

Protective factors include those that build cognitive reserve: education, social engagement, cognitive activity, aerobic exercise.

The single largest non-modifiable risk factor is age; the APOE ε4 allele is the most common genetic risk factor.

Read more